Neurocrine Biosciences Inc (STU:NB3)
€ 153.15 -1.9 (-1.23%) Market Cap: 15.37 Bil Enterprise Value: 14.57 Bil PE Ratio: 26.83 PB Ratio: 5.14 GF Score: 93/100

Neurocrine Biosciences Inc To Host R&D Day Transcript

Dec 16, 2025 / 05:00PM GMT
Release Date Price: €131.8 (+0.84%)
Todd Tushla
Neurocrine Biosciences Inc - Investor Relations

Good morning and good afternoon. My name is Todd Tusla. I'm the Vice President of investor relations at Neurocrine Biosciences, and on behalf of our entire company, welcome to our 2025 R&D day. Whether you're here in person, on the webcast, or reading the transcript, we're grateful for your time.

We will be making forward-looking statements today.

So I refer you to our latest SEC disclosures.

Our speakers for today from Nakkrine will be Kyle Gao, Chief Executive Officer, Sanjay Keswani, our Chief Medical Officer, and Jude Onya, our Chief Scientific Officer. As far as tenure at Nakrine, Sanjay joined us in June.

Jude joined us in 2021, and Kyle joined us in 2001.

Wow, that was a long time ago.

We're also fortunate to have with us today, Doctor John Crystal, a world leading expert in the field of neurology and psychiatry, and a professor at (

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot